Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.

Survodutide in adults with obesity and established cardiovascular disease or high cardiovascular risk showed non-inferior cardiovascular safety versus placebo (HR 0·89, 95% CI 0·67–1·18).

• Why it matters: Cardiovascular safety for this glucagon receptor–GLP-1 receptor dual agonist class was uncertain despite prior improvements in cardiometabolic markers.
• What they did: In a global, phase 3, double-blind, placebo-controlled trial (event-driven; 524 sites in 34 countries), adults with BMI ≥27 kg/m² were randomized to once-weekly survodutide (up-titrated to 3·6 mg or 6·0 mg) or placebo, targeting 189 primary events.
• The result: The primary composite endpoint occurred in 136/3671 participants on survodutide versus 76/1836 on placebo, with adverse events common on survodutide but serious and fatal events occurring at similar rates.

AI summary of the abstract · may contain errors · not medical advice · read the paper.